EPX 300 - Epygenix Therapeutics

Drug Profile

EPX 300 - Epygenix Therapeutics

Alternative Names: EPX-300

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epygenix Therapeutics
  • Class Antidepressants; Antiepileptic drugs
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dravet syndrome

Most Recent Events

  • 23 Aug 2017 EPX 300 - Epygenix Therapeutics receives Orphan Drug status for Dravet syndrome in USA
  • 10 Aug 2017 Preclinical trials in Dravet syndrome in USA before August 2017
  • 10 Aug 2017 Phase-II clinical trials in Dravet syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top